Actinium Pharmaceuticals, Inc. (delaware) · AMEX:ATNM
Actinium Pharmaceuticals, Inc. (delaware) — Actinium Pharmaceuticals — Investor Presentation (October 2014)
11 slides from Actinium Pharmaceuticals, Inc. (delaware)'s investor presentation, Oct 21, 2014
Slide 1: Key Opinion Leader Event: Emerging Therapies For Acute Myeloid Leukemia
Actinium Pharmaceuticals, Inc. Key Opinion Leader Event 4g N Emerging Therapies For Acute Myeloid Leukemia Featuring Dr. Joseph Jurcic ey CoLumMBIA UNIVERSITY ee Mepicar CENTER
Slide 2: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement Disclaimer ‘The contents ofthis presentation and the information which you are given a the time of these slides and the presentation have not been approved bby an authosized person within the meaning of the Financial Services and Markets Act 2000 (the “Act”), ReH
Slide 3: Company Description
Company Description A public biotechnology company using world class science to develop and commercialize antibody directed radioisotopes to target unmet medical needs in cancer.
Slide 4: Antibody Approaches Targeting Cancer Cells
Antibody Approaches Targeting Cancer Ce Cancer Treatment Options [Opportunity | Radiation ‘Monodonal Ansiboates (mAbs) ‘Treatment % 50% ¢ External radiation majority treatment —<10% + Abvays a pharmaceutical # Internal radiation has mostly no IP # Strong IP protection <3% ¢ Commoditized ~30% Mostly
Slide 5: ATNM's Product Pipeline
ATNM’s Product Pipeline | Tomab-B HSCT! (Bone Marrow) Bismab-A? AML Ackeniea G8) cae <a ums rene) ‘phe Sees | oS Actimab-A (f.d.) AML Third Program Not Disclosed ===> ‘Actimab-C Colon Cancer => Actimab-P Prostate Cancer ==> Actimab-Br Breast Cancer ==> 1 HSCT stands foc Hematopoiese Seem Call Tasipl
Slide 6: Market Positioning for Iomab-B, Actimab-A
Market Positioning for Iomab-B, Actimab-A ATNM products target both treatment stages for AML patients over 55 years of age Diagnosis Treatment Response ‘Treatments ATNM Pipeline Drugs Positive Response > MM Negative Response | 6
Slide 7: Iomab-B A New Treatment Paradigm
Iomab-B A New Treatment Paradigm v Provides treatment alternative to patients with no options v Significantly expands patient population eligible for BMT ¥ Provides potentially a faster way of performing BMT with fewer side effects ¥ Minimizes transplant related mortality Y Significantly increases c
Slide 8: Hum — Alpha Program
Hum 195 — Alpha Program Bismab-A => Actimab-A Second generation Actimab-A 500x more potent than Bismab-A 18 Generation Bismab-A Profile Actimab-A Advantages Target: + AML ¢ AML Effectiveness: ¢ Proof of concept in humans + 500x more potent than Bismab-A Clinical Stage: ¢ Promising results in Phase I
Slide 9: Hum — Alpha Program
Hum 195 — Alpha Program Bismab-A monotherapy =e Bismab A + IDAC cytoreduction ~ Patients: Rel/ref, >60hi risk newly diagnosed MTD: ImCi/kg, Early mortality: 10% BM blast reduction >50%: 62% of patients CR: 33% in high tisk Median OS 7.7m (13.7m for responders) (vs ‘a 1.8m in 260 hi tisk newly diagno
Slide 10: Near-term Value Drivers
Near-term Value Drivers Potential milestones in next 12-24 months * Tomab-B + Actimab-A ¥ Complete Phase II Protocol — Establish proof of concept ¥ Start CGMP mAb mfg. — Complete mfg, improvements Y ‘Start drug mfg cGMP process — Establish clear pathway to approval — Complete cGMP mAb mfg — Expand i
Slide 11: Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. Key Opinion Leader Event 4g N Emerging Therapies For Acute Myeloid Leukemia Featuring Dr. Joseph Jurcic ey CoLumMBIA UNIVERSITY ee Mepicar CENTER
Actinium Pharmaceuticals — Investor Presentation (October 2014) on 6ix